Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
21 mai 2024 00h40 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of...
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
21 mai 2024 00h40 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of...
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
14 mai 2024 11h45 HE
|
Idorsia Pharmaceuticals Ltd
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same...
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
14 mai 2024 11h45 HE
|
Idorsia Pharmaceuticals Ltd
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same...
Bondholders approve amended terms of the 2024 convertible bonds
06 mai 2024 12h35 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the...
Bondholders approve amended terms of the 2024 convertible bonds
06 mai 2024 12h35 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the...
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
01 mai 2024 12h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRThe proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder...
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
01 mai 2024 12h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LRThe proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder...
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
26 avr. 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin...
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
26 avr. 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin...